Ferring Pharmaceuticals

Press Release

Philadelphia – October 18, 2004 – The Society for Reproductive Endocrinology and Infertility (SREI) announced today that Ferring Pharmaceuticals will be the new sponsor of its annual educational Fellows’ Retreat Program from 2005 through 2007. The announcement was made by William Schlaff, M.D., president of SREI, at a reception hosted by Ferring at the Annual Meeting of the American Society for Reproductive Medicine in Philadelphia.

“We are grateful to Ferring for providing this welcome support for our annual Fellows’ Retreat over the next three years,” said Dr. Schlaff. “Ferring’s unrestricted educational grant enables SREI to provide an intensive educational forum for reproductive endocrinology fellows that complements their academic training.”

The Fellows’ Retreat has been held every August for the past 12 years. The program offers first- and third-year fellows an opportunity to focus on issues that are important to their career planning and development. Topics include aspects of their future practice environment, such as private practice versus academic setting; research or clinical practice; and how to balance work and personal life by making sound decisions for themselves and their families. The Retreat also provides fellows with the opportunity to meet junior faculty and senior leadership.

“We are delighted to partner with SREI to support the practice of reproductive endocrinology and the practical education of future REs,” said Wayne Anderson, president of Ferring Pharmaceuticals. “Now that these highly trained physicians are in the final stage of their basic medical education, they will benefit from the practical training provided at the retreat to prepare them for their future.”

ABOUT SREI
The Society for Reproductive Endocrinology and Infertility is made up of Obstetrician-Gynecologists with advanced education, research and professional skills in Reproductive Endocrinology & Infertility. These highly trained and qualified physicians treat Reproductive Disorders that affect children, women, men, the mature woman, and infertility in both men and women.

ABOUT FERRING PHARMACEUTICALS
Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, markets Bravelle™, Repronex™ and Novarel™ in the U.S. to infertility specialists and their patients. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 888-337-7464 or visit www.ferringusa.com or www.ferringfertility.com.